Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchCannabidiolCannabidiol (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

    
  
Cannabidiol for COVID-19
7 studies from 92 scientists
16,883 patients in 3 countries
Statistically significant lower risk for ventilation and ICU.
Non-symptomatic case results show 8% [-14-25%] lower risk, however symptomatic results show 61% [-53-451%] higher risk.
COVID-19 Cannabidiol studies. Apr 2024. c19early.org
0 0.5 1 1.5+ All studies -19% Mortality 0% Hospitalization -43% Cases -10% RCTs -557% Symptomatic -61% Prophylaxis -11% Late -557% Favorscannabidiol Favorscontrol
Apr 17
Covid Analysis Cannabidiol for COVID-19: real-time meta analysis of 7 studies
Meta analysis using the most serious outcome reported shows 19% [-38‑128%] higher risk, without reaching statistical significance. While non-symptomatic case results show 8% [-14‑25%] improvement, symptomatic results..
Dec 30
2023
Scott et al., Journal of Clinical Medicine, doi:10.3390/jcm13010227 Cannabinoids and the Endocannabinoid System in Early SARS-CoV-2 Infection and Long COVID-19—A Scoping Review
Review of the potential therapeutic role of cannabinoids and the endocannabinoid system in SARS-CoV-2 infection and long COVID-19. Authors note that early in infection, cannabinoids may prevent viral entry, mitigate oxidative stress, and ..
Jan 28
2023
Mannumbeth Renjithlal et al., SSRN Electronic Journal, doi:10.2139/ssrn.4336513 Cannabis Use and COVID-19 Hospitalization Outcomes. A Retrospective Study
56% lower mortality (p<0.0001), 25% lower ventilation (p<0.0001), and 6% longer hospitalization (p=0.0009). Retrospective 1,657,800 COVID-19 hospitalizations in the USA including 13,095 patients with cannabis use disorder, showing lower risk of mortality with cannabis use disorder. The text and Table S2 have conflicting results for mortality: 0..
Aug 29
2022
Ramakrishnan et al., The Journal of Clinical Psychiatry, doi:10.4088/JCP.21m14332 Impact of Cannabis Use, Substance Use Disorders, and Psychiatric Diagnoses on COVID-19 Outcomes
47% higher hospitalization (p=0.0001). Retrospective 6,291 COVID-19 patients in the USA, showing higher mean hospital admissions and higher maximum length of hospitalization with cannabis use disorder. Results for cannabis use disorder patients may differ from other use of can..
Aug 5
2022
Shover et al., Journal of Cannabis Research, doi:10.1186/s42238-022-00152-x Cannabis consumption is associated with lower COVID-19 severity among hospitalized patients: a retrospective cohort analysis
2% lower mortality (p=0.57), 5% lower ventilation (p=0.02), 9% lower ICU admission (p=0.02), and 3% lower need for oxygen therapy (p=0.27). Retrospective 1,831 hospitalized COVID-19 patients in the USA, showing lower mechanical ventilation and ICU admission, but no significant difference in mortality.
Jun 22
2022
Lehrer et al., Chronic Diseases and Translational Medicine, doi:10.1002/cdt3.38 Association of cannabis with chronic obstructive pulmonary disease and COVID-19 infection
24% more cases (p=0.009). UK Biobank retrospective showing a higher risk of COVID-19 cases with a history of cannabis use.
Mar 31
2022
Merianos et al., Addictive Behaviors, doi:10.1016/j.addbeh.2021.107170 Concurrent use of e-cigarettes and cannabis and associated COVID-19 symptoms, testing, and diagnosis among student e-cigarette users at four U.S. Universities
212% more symptomatic cases (p<0.0001) and 3% more cases (p=0.33). Retrospective 800 e-cigarette users in the USA, showing higher risk of COVID-19 diagnosis and symptoms with cannabis use.
Mar 8
2022
Huang et al., Frontiers in Public Health, doi:10.3389/fpubh.2022.829715 Cannabis use is associated with lower COVID-19 susceptibility but poorer survival
181% higher mortality (p=0.04) and 19% fewer cases (p=0.0001). UK Biobank retrospective with 13,099 cannabis users, showing a lower risk of COVID-19 infection, however regular users had a significantly higher risk of mortality.
Jan 20
2022
Nguyen et al., Science Advances, doi:10.1126/sciadv.abi6110 (date from preprint) Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses
50% fewer cases (p=0.006). Retrospective 1,212 patients in the USA with a history of seizure-related conditions, showing patients treated with CBD100 had significantly lower incidence of COVID-19 cases compared to a matched control group. In Vitro study showing CBD..
Jan 10
2022
van Breemen et al., Journal of Natural Products, doi:10.1021/acs.jnatprod.1c00946 Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants
In Vitro study showing that cannabigerolic acid and cannabidiolic acid inhibited SARS-CoV-2 entry into cells.
Oct 7
2021
Crippa et al., Cannabis and Cannabinoid Research, doi:10.1089/can.2021.0093 Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
557% higher hospitalization (p=0.25) and 33% slower recovery (p=0.21). RCT 105 patients recruited in an ER in Brazil, 49 treated with CBD, showing no significant differences with treatment. 300mg CBD for 14 days. For discussion see [liebertpub.com].
Feb 17
2021
Malinowska et al., International Journal of Molecular Sciences, doi:10.3390/ijms22041986 Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19
Review of the potential benefits and concerns for the use of cannabidiol in the treatment of COVID-19.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit